Literature DB >> 10781856

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.

R E Humphreys1, S Adams, G Koldzic, B Nedelescu, E von Hofe, M Xu.   

Abstract

We previously found that peptide Ii77-92 from the immunoregulatory Ii protein significantly enhances the binding of antigenic peptides to MHC class II molecules. Now a series of hybrids have been constructed linking LRMK, the active core region of the Ii77-92 peptide, to an antigenic epitope of cytochrome C. In vitro T cell hybridoma stimulation by some of these hybrids is up to 250 times more potent than by the antigenic peptide. The biological activities of the hybrids were tested in terms of length and composition of the linker. Simple spacers containing a polymethylene bridge (-HN-CH(2)-CH(2)-CH(2)-CH(2)-CO(2)-) were fully active in these hybrids which can enhance vaccination with MHC class II-presented epitopes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781856     DOI: 10.1016/s0264-410x(00)00067-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Design of a ProDer f 1 vaccine delivered by the MHC class II pathway of antigen presentation and analysis of the effectiveness for specific immunotherapy.

Authors:  Zhiming Liu; Yuxin Jiang; Chaopin Li
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

2.  MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.

Authors:  Courtney L Erskine; Christopher J Krco; Karen E Hedin; Nancy D Borson; Kimberly R Kalli; Marshall D Behrens; Sabrina M Heman-Ackah; Eric von Hofe; Peter J Wettstein; Mansour Mohamadzadeh; Keith L Knutson
Journal:  J Immunol       Date:  2011-05-25       Impact factor: 5.422

3.  MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Authors:  Eleftheria A Anastasopoulou; Ioannis F Voutsas; Michael Papamichail; Constantin N Baxevanis; Sonia A Perez
Journal:  Oncoimmunology       Date:  2016-05-02       Impact factor: 8.110

4.  Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.

Authors:  E A Mittendorf; A Ardavanis; J Symanowski; J L Murray; N M Shumway; J K Litton; D F Hale; S A Perez; E A Anastasopoulou; N F Pistamaltzian; S Ponniah; C N Baxevanis; E von Hofe; M Papamichail; G E Peoples
Journal:  Ann Oncol       Date:  2016-03-30       Impact factor: 32.976

5.  Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis.

Authors:  Brady J Hurtgen; Chiung-Yu Hung; Gary R Ostroff; Stuart M Levitz; Garry T Cole
Journal:  Infect Immun       Date:  2012-09-04       Impact factor: 3.441

6.  Boosting immune response with the invariant chain segments via association with non-peptide binding region of major histocompatibility complex class II molecules.

Authors:  Fangfang Chen; Fantao Meng; Ling Pan; Fazhi Xu; Xuelan Liu; Weiyi Yu
Journal:  BMC Immunol       Date:  2012-09-27       Impact factor: 3.615

Review 7.  Breast Cancer Vaccines: Disappointing or Promising?

Authors:  Si-Yuan Zhu; Ke-Da Yu
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

8.  Development and evaluation of a multi-epitope subunit vaccine against group B Streptococcus infection.

Authors:  Yumin Zhang; Song Liang; Shiyu Zhang; Shidan Zhang; Yong Yu; Huochun Yao; Yongjie Liu; Wei Zhang; Guangjin Liu
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

Review 9.  Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.

Authors:  Katie L Flanagan; Emma Best; Nigel W Crawford; Michelle Giles; Archana Koirala; Kristine Macartney; Fiona Russell; Benjamin W Teh; Sophie Ch Wen
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.